Orgovyx (relugolix) causes side effects that are broadly consistent with what happens when testosterone levels drop sharply, because that is exactly what the drug is designed to do. Hot flushes are the most common complaint, affecting roughly half to 60 percent of users, followed by fatigue, diarrhea, and musculoskeletal aches. What sets Orgovyx apart from the older injectable hormone therapies it competes with is a meaningfully lower rate of serious cardiovascular events, a distinction that matters for the many prostate cancer patients who already carry heart-related risk factors.
The Most Frequently Reported Side Effects
Because Orgovyx works by blocking the hormone signal that tells the body to produce testosterone, most of its side effects are predictable consequences of very low testosterone rather than quirks of the drug molecule itself. The five complaints that show up most often in FDA adverse-event reports are hot flushes, fatigue, general weakness, constipation, and muscle pain.1PubMed Central. Adverse events analysis of Relugolix (Orgovyx®) for prostate cancer based on the FDA Adverse Event Reporting System (FAERS) All of these are also listed on the drug’s prescribing information, so none come as a surprise to oncologists. A structured review of clinical trials found that hot flushes occurred in about 50 to 60 percent of patients, and diarrhea was somewhat more common with Orgovyx than with the injectable comparator leuprolide, though the diarrhea was generally mild.2PubMed Central. Clinical Effectiveness of Oral Relugolix in Advanced Prostate Cancer: A Structured Review of Current Primary Research
It is worth noting what “consistent with testosterone suppression” really means in day-to-day life. Hot flushes can arrive without warning multiple times a day. Fatigue is not just feeling a bit tired; some men describe it as a bone-deep exhaustion that interferes with work and hobbies. Muscle aches and general weakness make physical activity harder at the exact time when exercise would help manage other side effects like weight gain and mood changes. None of these effects are unique to Orgovyx; they happen with every form of androgen deprivation therapy, including injectable drugs and surgical castration.3PubMed Central. Relugolix: A Review in Advanced Prostate Cancer
Why the Cardiovascular Picture Is Different
Heart-related complications are a well-known concern with any hormone therapy for prostate cancer, and this is where Orgovyx has drawn the most attention. In the large Phase 3 HERO trial, major adverse cardiovascular events occurred in about 2.9 percent of men on Orgovyx compared with 6.2 percent on leuprolide, roughly halving the risk.4PubMed Central. Clinical Effectiveness of Oral Relugolix in Advanced Prostate Cancer: A Structured Review of Current Primary Research That finding has been broadly supported by other analyses. A meta-analysis pooling data from trials comparing GnRH antagonists (the drug class Orgovyx belongs to) with older GnRH agonists found that the antagonist group had roughly 43 percent fewer cardiovascular events overall.5European Heart Journal – Cardiovascular Pharmacotherapy. The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer An independent analysis of the FDA’s adverse-event reporting system also found fewer cardiovascular reports with GnRH antagonists than with agonists, both when used alone and when combined with other treatments.6PubMed Central. Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS)
The practical upshot is that if you already have a history of heart disease, heart failure, or a prior cardiovascular event, Orgovyx may carry a meaningful safety advantage over injectable alternatives. That advantage was one of the key selling points when the FDA approved the drug, and preference research confirms that patients with cardiovascular comorbidities show a stronger preference for the oral pill over injections.7PubMed Central. Patients’ Preferences for Attributes of Oral vs Injectable Androgen Deprivation Therapy in Prostate Cancer: A Discrete Choice Experiment
That said, cardiovascular safety with Orgovyx is not completely worry-free. A pharmacovigilance study looking specifically at relugolix signals in the FAERS database found a notable association with electrocardiogram abnormalities and palpitations.8PubMed. Exploration of cardiac adverse events associated with relugolix and degarelix: a multi-center pharmacovigilance study based on the FAERS database Pharmacovigilance signals are not the same as proven causal relationships, but they suggest that even though Orgovyx looks better than older therapies on the cardiovascular front, heart-related monitoring still matters. If you experience a racing or irregular heartbeat while on the drug, it is worth bringing up with your care team rather than dismissing it.
Sexual Function Declines Significantly
One of the most distressing side effects for many men is the steep decline in sexual function. A study tracking patient-reported outcomes in men receiving Orgovyx before radiation therapy found that overall sexual function scores dropped by more than 30 points on a standardized scale, falling from a baseline of about 48 to roughly 18. Erection ability, orgasm ability, and erection frequency all declined by similar magnitudes, and every one of those changes was large enough to be considered clinically meaningful, not just a statistical blip.9PubMed Central. Impact of neoadjuvant relugolix on patient-reported sexual function and bother
Post-marketing surveillance has also flagged several sexual and reproductive side effects that were not prominently featured in the original trial data. These include erectile dysfunction, decreased libido, testicular atrophy, male genital atrophy, and breast tissue enlargement (gynecomastia).10PubMed. Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system None of these are surprising when testosterone is suppressed to castrate levels, but the real-world reporting data confirms that they occur with Orgovyx specifically, not just as a theoretical class effect. For men in relationships, this aspect of treatment often affects quality of life more than any other side effect, and it is worth discussing openly with both your oncologist and your partner before starting therapy.
Mood Swings and Cognitive Slowing
Low testosterone affects the brain as well as the body, and Orgovyx is no exception. In an analysis of FDA adverse-event reports, mood swings showed a strong disproportionality signal, meaning they were reported far more often than you would expect by chance. An even stronger signal appeared for bradyphrenia, a clinical term for noticeably slowed thinking. That signal was among the highest in the psychiatric category, though the total number of reports was small.11PubMed Central. Adverse events analysis of Relugolix (Orgovyx®) for prostate cancer based on the FDA Adverse Event Reporting System (FAERS)
Slowed cognition on hormone therapy is sometimes dismissed as “chemo brain” or normal aging, but a growing body of research across all forms of androgen deprivation therapy suggests it is a genuine pharmacological effect. If you or a family member notice that it takes longer to find words, follow conversations, or make routine decisions after starting Orgovyx, that observation is consistent with what the adverse-event data show. It does not necessarily mean the drug should be stopped, but it is worth tracking and discussing, especially for men who are still working or managing complex daily responsibilities.
The Oral Pill Advantage and Its Practical Trade-Offs
Much of the appeal of Orgovyx comes from the fact that it is a daily pill rather than an injection given every few months. Patient preference studies bear this out: holding cost constant, the mode of administration was one of the two most important attributes men considered when choosing a hormone therapy, along with impact on sexual interest. Across all subgroups studied, patients preferred a once-daily pill over less-frequent injections, and that preference was especially strong among men with cardiovascular conditions and among racial and ethnic minorities.12PubMed Central. Patients’ Preferences for Attributes of Oral vs Injectable Androgen Deprivation Therapy in Prostate Cancer: A Discrete Choice Experiment
But a daily pill introduces its own practical headaches. You have to remember to take it every single day, preferably at the same time. Missing doses can allow testosterone to start creeping back up, which undermines the whole point of treatment. The drug also interacts with certain other medications, particularly strong inhibitors or inducers of a liver enzyme called CYP3A4 and a gut transporter called P-glycoprotein. If you are taking drugs for seizures, HIV, fungal infections, or certain heart rhythm problems, your oncologist needs to know so they can check for interactions. The first dose of Orgovyx is a loading dose of three tablets taken together, followed by one tablet daily thereafter. If you take certain interacting medications, the effective level of relugolix in your blood can change significantly, which means your doctor may need to adjust your regimen or monitor you more closely.
Testosterone Recovery After Stopping
One of the clearest advantages Orgovyx has over injectable GnRH agonists like leuprolide shows up after you stop treatment. In the HERO trial’s follow-up data, 54 percent of men who had been on Orgovyx recovered their testosterone to above 280 ng/dL within 90 days of stopping the drug, compared with just about 3 percent of men who had been on leuprolide.13European Urology Oncology. Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study The median time to recovery was 86 days for the Orgovyx group versus 112 days for leuprolide, and the difference in actual testosterone levels at the 90-day mark was dramatic: about 271 ng/dL for men who had taken Orgovyx versus just 12 ng/dL for men who had been on leuprolide.14PubMed Central. Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer
This faster recovery matters because many of the side effects discussed above, including fatigue, sexual dysfunction, mood changes, and hot flushes, are driven by low testosterone. The sooner testosterone levels climb back to a functional range, the sooner those symptoms begin to ease. For men receiving short-course hormone therapy alongside radiation, for instance, this can mean the difference between months of lingering side effects and a relatively quick return to baseline. Of course, recovery is not guaranteed for everyone: older men who had lower testosterone before starting treatment tend to recover more slowly, and some men on prolonged courses of any hormone therapy never fully return to their pre-treatment levels.
Skin Reactions, Though Rare
Dermatologic side effects are not commonly discussed with Orgovyx, but they do show up. In a clinical trial combining relugolix with other prostate cancer drugs, rash was among the most commonly reported adverse events in one treatment arm.15PubMed Central. Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial More unusually, there is a published case of a biopsy-confirmed lichenoid drug eruption, a type of widespread, itchy rash that mimics a skin condition called lichen planus, directly attributed to relugolix. The case was considered the first documented biopsy-proven skin reaction linked to any GnRH analogue.16PubMed Central. A case of lichenoid drug eruption associated with relugolix
If you develop a new rash after starting Orgovyx, especially one that is symmetrically distributed across the body and itchy, mention it to your doctor even if you assume it is unrelated to your cancer treatment. Drug eruptions can sometimes be managed without stopping the medication, but they need to be correctly identified first.
Liver and Metabolic Changes to Watch For
Clinical trial data in humans have not flagged serious liver toxicity as a major concern with Orgovyx, but preclinical work suggests the possibility should not be entirely dismissed. A study of a long-acting formulation of relugolix in animal models found statistically significant increases in liver enzymes (ALT and AST), along with rises in triglyceride levels, suggesting potential effects on liver function and fat metabolism.17European Journal of Pharmaceutical Sciences. Pharmacokinetics and pharmacodynamics studies of Relugolix long-acting microcrystalline formulation in male Beagle dogs These findings come from animal models, not from human trials, so they cannot be directly applied to your experience on the drug. Still, they provide a reason to keep up with routine blood work, including liver function panels, while on therapy. Androgen deprivation therapy in general is known to alter lipid profiles and increase the risk of metabolic syndrome, so your care team will likely be monitoring these markers regardless.
Combination Therapy Can Shift the Side-Effect Profile
Orgovyx is sometimes used alongside other prostate cancer drugs like abiraterone or apalutamide. When drugs are combined, the side-effect picture can change. In a 52-week trial of relugolix combined with either abiraterone or apalutamide, most adverse events remained grade 1 or 2, meaning they were mild to moderate. However, hypertension was the most commonly reported adverse event in the abiraterone combination arm, while rash was most common with apalutamide.18PubMed Central. Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial Neither hypertension nor rash at those rates is alarming on its own, but the point is that what you can expect from Orgovyx alone is not necessarily identical to what you will experience on a combination regimen. If your oncologist recommends adding another drug, ask specifically about how the combined side-effect profile differs from Orgovyx monotherapy.
Unexpected Signals in Post-Marketing Data
One of the benefits of a drug being on the market for several years is that the real-world safety picture fills in beyond what clinical trials captured. A large disproportionality analysis of over 5,600 adverse-event reports linked to relugolix in the FAERS database identified 70 significant adverse-event signals. Among those that were not prominently described in the original clinical trials were erectile dysfunction, gynecomastia, testicular atrophy, male genital atrophy, and decreased libido.19PubMed. Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system The word “unexpected” in the pharmacovigilance literature does not mean these effects are biologically surprising; it means they were not part of the drug’s original labeling at the level of emphasis their real-world frequency might justify.
Post-marketing data also revealed that certain testosterone-related laboratory abnormalities, such as increases in blood testosterone (a paradoxical finding that may reflect inconsistent dosing or drug interactions) and male genital atrophy, were among the strongest disproportionality signals.20PubMed Central. Adverse events analysis of Relugolix (Orgovyx®) for prostate cancer based on the FDA Adverse Event Reporting System (FAERS) Blood testosterone increases reported in the database likely reflect real-world adherence issues: because Orgovyx is a daily pill, a few missed days can cause testosterone to rebound more quickly than it would with a depot injection still slowly releasing drug in the body. This is one of the hidden costs of the convenience of a pill. If you struggle with medication adherence, that is something to be honest about with your care team, because it directly affects both efficacy and the pattern of side effects you may experience.
Renal Safety Appears Reassuring
Kidney function is always a background concern with any long-term medication, particularly in an older patient population that may already have reduced renal reserve. Preclinical data comparing oral and injectable formulations of relugolix found no evidence of kidney damage: urinalysis markers including protein levels, specific gravity, and pH all stayed within normal limits, and there were no signs of glomerular damage or urinary tract inflammation.21Scientific Reports. Comparative preclinical assessment of relugolix tablets and relugolix intravenous injection While preclinical results do not perfectly predict human outcomes, the absence of any renal red flags is consistent with what has been observed in clinical trials and post-marketing surveillance, where kidney problems have not emerged as a notable concern. Routine monitoring of kidney function is still standard practice for men on hormone therapy, but Orgovyx does not appear to add any specific renal risk on top of what aging and cancer treatment already bring.